Valneva, the French vaccine company whose COVID-19 vaccine was championed by the UK government only to have its commercial deal cancelled, has recorded a success in its product’s Phase III study.
Its inactivated adjuvanted COVID-19 vaccine candidate, VLA2001, went head to head against AstraZeneca’s Vaxzevria in the COV-COMPARE (VLA2001-301) immunogenicity study of over 4,000 participants, which found it generated on average a 39% higher level of neutralizing antibodies against SARS-CoV-2 than its rival
